Last reviewed · How we verify
Trivalent OPV Sanofi Pasteur
Trivalent OPV Sanofi Pasteur is a vaccine that stimulates the body's immune response to protect against poliovirus.
Trivalent OPV Sanofi Pasteur is a vaccine that stimulates the body's immune response to protect against poliovirus. Used for Prevention of poliomyelitis.
At a glance
| Generic name | Trivalent OPV Sanofi Pasteur |
|---|---|
| Also known as | tOPV |
| Sponsor | Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It works by introducing a weakened form of the poliovirus to the body, which triggers an immune response and helps the body develop antibodies to fight the virus. This provides immunity against poliovirus types 1, 2, and 3.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (PHASE4)
- Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |